Key result
In pregnant women with prosthetic heart valves, the live birth rate was 56.3% (95% CI 42.3-69.3) with anti-Xa adjusted enoxaparin compared to 20.0% (95% CI 2.0-64.0) with warfarin.
Why the study?
Maternal and fetal outcomes needed review in pregnant women with prosthetic heart valves requiring anticoagulation.
What are the maternal and fetal outcomes in pregnant women with prosthetic heart valves treated with anticoagulation?
Comparison
Anti-Xa adjusted enoxaparin vs continued warfarin
Design
Single-centre retrospective record review
Authors
Loading...
Enoxaparin may support better fetal outcomes than warfarin in pregnant women with prosthetic valves; leaves open randomized confirmation of safety and efficacy.
Observational (n=53)
No
What are the maternal and fetal outcomes in pregnant women with prosthetic heart valves treated with anticoagulation?
Absolute Event Rate: 56.3% vs 20%
Anti-Xa adjusted low molecular weight heparin throughout pregnancy represents an effective anticoagulation option for pregnant women with prosthetic heart valves in low-middle-income countries.
Rhemtula et al. (2024) conducted an observational in pregnant women with prosthetic heart valves (n=53). Anti-Xa adjusted enoxaparin vs. warfarin was evaluated on live birth rates. In pregnant women with prosthetic heart valves, the live birth rate was 56.3% (95% CI 42.3-69.3) with anti-Xa adjusted enoxaparin compared to 20.0% (95% CI 2.0-64.0) with warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: